One confounding factor in this study was the pre-treatment of patients with unlabeled cetuximab to occupy non-malignant binding sites as invariably EGFR binding sites on the tumor could also be saturated which would have had an impact on subsequent imaging. The gene discussed is EGFR; the disease is neoplasm.